{"id":"pro-2000-5-gel","safety":{"commonSideEffects":[{"rate":"null","effect":"Local irritation"}]},"_chembl":{"chemblId":"CHEMBL1234624","moleculeType":"Small molecule","molecularWeight":"208.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PRO 2000/5 Gel contains a sulfonated polysaccharide that binds to the HIV-1 envelope glycoprotein gp120, preventing it from interacting with the host cell receptor CD4 and thus inhibiting viral entry. This mechanism of action is thought to be effective in preventing HIV-1 transmission during sexual intercourse.","oneSentence":"PRO 2000/5 Gel is a microbicide that prevents HIV-1 transmission by inhibiting viral entry into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:07.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of HIV-1 transmission during sexual intercourse"}]},"trialDetails":[{"nctId":"NCT00074425","phase":"PHASE2","title":"BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"HIV Infections","enrollment":3101},{"nctId":"NCT00016536","phase":"PHASE1","title":"Effects of BufferGel and PRO 2000/5 Gel in Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00262106","phase":"PHASE3","title":"Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2005-10","conditions":"HIV Infections, Gonorrhea, Chlamydial Infections","enrollment":9404},{"nctId":"NCT00081640","phase":"PHASE1","title":"Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00006207","phase":"PHASE1","title":"Safety and Tolerability of the Vaginal Gel PRO 2000/5","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PRO 2000/5 Gel","genericName":"PRO 2000/5 Gel","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PRO 2000/5 Gel is a vaginal gel that has been studied for its potential to prevent HIV infections, gonorrhea, chlamydial infections, and genital herpes. It was evaluated in a clinical trial (NCT00262106) as a treatment to prevent vaginally acquired HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}